December 7, 2018 — The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the Planmed Verity cone beam computed tomography (CBCT) orthopedic imaging solution on Nov. 30, 2018.
The improved Planmed Verity now offers enhanced image quality as well as new options for head and neck imaging, the Planmeca Ultra Low Dose imaging protocol for lower patient doses, and Planmeca CALM algorithm for motion artifact correction.
The new enhancements include the iterative Planmeca CALM algorithm, which reduces artifacts caused by patient movement. The algorithm is especially useful in challenging weight-bearing examinations in which patients have a tendency to move. Meanwhile, the Planmeca Ultra Low Dose (ULD) imaging protocol enables reduction of already low effective patient doses even further, without compromising diagnostic image quality.
For more information: www.planmed.com
June 24, 2026 
